Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 14, Number 2—February 2008
Research

Cost-effectiveness of Antiviral Stockpiling and Near-Patient Testing for Potential Influenza Pandemic

M. Ruby Siddiqui*Comments to Author  and W. John Edmunds*
Author affiliations: *Health Protection Agency, London, UK;

Main Article

Figure 5

Incremental cost-effectiveness of the test-treat strategy over the treat-only strategy during a pandemic wave (antiviral [AV] stockpile = 14.6 million courses, test stockpile = number of cumulative influenza-like [ILI] cases, clinical attack rate = 25%). QALY, quality-adjusted life year.

Figure 5. Incremental cost-effectiveness of the test-treat strategy over the treat-only strategy during a pandemic wave (antiviral [AV] stockpile = 14.6 million courses, test stockpile = number of cumulative influenza-like [ILI] cases, clinical attack rate = 25%). QALY, quality-adjusted life year.

Main Article

Page created: July 08, 2010
Page updated: July 08, 2010
Page reviewed: July 08, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external